secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001104659-24-010945
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome to acquire AL102 Phase 3 desmoid tumor asset from Ayala for $20M cash + $30M stock
--------------------------------------------------------------------------------

- Immunome will acquire AL102 and AL101 from Ayala for $20M cash and ~$30M in stock (2.18M shares).
- Up to $37.5M in development and commercial milestone payments; closing requires Ayala stockholder approval.
- AL102 is a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; Phase 2 data showed 75% ORR.
- AL102 granted FDA Orphan Drug Designation in Nov 2023; desmoid tumors affect ~1,650 diagnosed annually in U.S.
- Transaction to complement Immunome's targeted cancer pipeline; Ayala's stock trades OTCQX under ADXS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924010945/0001104659-24-010945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924010945/tm245249d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-010945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer